FDA Approves Ultragenyx Gene Therapy for Sanfilippo Syndrome
RARE is trading near its 52-week low of $12.73 (14% above the low) on elevated volume (2.6× avg).
Summary
The FDA approved Ultragenyx's gene therapy UX111, also known as FAYUVI, for Sanfilippo syndrome type A, a rare and fatal pediatric neurodegenerative disorder. This is the company's second gene therapy approval in under a month, following GENGLYCOS for GSDIa in August. The approval validates Ultragenyx's gene therapy platform and opens a new commercial market, though the patient population is small. The company has not yet disclosed pricing or launch timing. This follows the recent failure of apazunersen in Angelman syndrome, making this approval a critical positive catalyst for the stock, which jumped on the news.
At the time of this announcement, RARE was trading at $14.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $12.73 to $39.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.